ストックスクリーナーアプリを入手
9.43
0.86%
0.08
前日終値:
$9.35
開ける：
$9.23
24時間の取引高:
23,008
Relative Volume:
0.95
時価総額：
$94.66M
収益：
$23.14M
当期純損益:
$-9.47M
株価収益率:
-10.68
EPS:
-0.8827
ネットキャッシュフロー:
$-25.88M
1週間 パフォーマンス:
-2.28%
1か月 パフォーマンス:
+5.60%
6か月 パフォーマンス:
+82.05%
1年 パフォーマンス:
-35.54%
1日の値動き範囲:
$8.9709
$9.65
1週間の範囲:
$8.88
$9.905
52週間の値動き範囲:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
名前
Atara Biotherapeutics Inc
セクター
電話
805-623-4211
住所
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
9.43 | 94.66M | 23.14M | -9.47M | -25.88M | -0.8827 |
VRTX
Vertex Pharmaceuticals Inc
|
535.17 | 135.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.09 | 84.33B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
202.63 | 80.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.76 | 55.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-05-08 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2026-01-13 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-11-09 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-07-20 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-07-13 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-07-13 | ダウングレード | Stifel | Buy → Hold |
| 2022-05-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-05-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-30 | 開始されました | Evercore ISI | Outperform |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-23 | アップグレード | Citigroup | Neutral → Buy |
| 2019-11-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-09-27 | ダウングレード | Goldman | Neutral → Sell |
| 2019-09-16 | ダウングレード | Jefferies | Buy → Hold |
| 2019-06-04 | アップグレード | Citigroup | Sell → Neutral |
| 2019-05-30 | 開始されました | ROTH Capital | Buy |
| 2019-05-23 | 開始されました | Stifel | Buy |
| 2019-01-23 | 開始されました | Mizuho | Buy |
| 2018-04-10 | 開始されました | JP Morgan | Overweight |
| 2018-03-16 | 開始されました | Guggenheim | Neutral |
| 2018-03-05 | 繰り返されました | Jefferies | Buy |
| 2018-02-28 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | ダウングレード | Citigroup | Neutral → Sell |
| 2018-01-03 | アップグレード | Citigroup | Sell → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
すべてを表示
Atara Biotherapeutics Inc (ATRA) 最新ニュース
Press Release Distribution & Media Outreach Platform for PR Agencies - ACCESS Newswire
FDA accepts resubmitted application for Atara’s tab-cel therapy - Investing.com
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration - FinancialContent
Atara Biotherapeutics Share PriceATRA, RNS News, Articles, Quotes, & Charts (NASDAQ:ATRA) - Proactive financial news
Atara Biotherapeutics Inc (ATRA) Stock Price, Trades & News - GuruFocus
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Precision Trading with Atara Biotherapeutics Inc. (ATRA) Risk Zones - Stock Traders Daily
Atara, Pierre Fabre take third shot at FDA approval of Ebvallo - BioWorld News
Atara Partner Resubmits Tabelecleucel FDA Application - grafa.com
Atara Biotherapeutics (ATRA) Sees FDA Resubmission for Tabelecle - GuruFocus
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration - Business Wire
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - accessnewswire.com
Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Independent Director of Atara Biotherapeutics Picks Up 272% More Stock - simplywall.st
New Form 4 - Moomoo
Atara Biotherapeutics (ATRA) Director Brian Cherry Buys 104,166 Shares - GuruFocus
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares - Investing.com Canada
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares - Investing.com Australia
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares - Investing.com Nigeria
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares - Investing.com India
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares - investing.com
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares By Investing.com - Investing.com South Africa
Atara Biotherapeutics Director Purchased Shares Worth Over $999K - TradingView
(ATRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
ATRA Shareholders Have Opportunity to Lead Atara Biotherapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Atara Biotherapeutics president and CEO sells $40,882 in shares By Investing.com - Investing.com Nigeria
Atara Biotherapeutics president and CEO sells $40,882 in shares - Investing.com India
Atara Biotherapeutics (ATRA) employee plans 5,062-share tax sale - Stock Titan
Atara Biotherapeutics president and CEO sells $40,882 in shares - Investing.com
Atara (ATRA) Results Breakdown: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report Move: The Stock Records a 1.26% Increase at the CloseProfit Growth Outlook - vinanet.vn
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Why (ATRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake - Stock Titan
Atara Biotherapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | ATRA | US0465132068 - marketscreener.com
Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates - Investing.com Nigeria
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics cuts costs 87%, extends cash runway to mid-2027 - scanx.trade
Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates - Investing.com
Is Atara Biotherapeutics Inc (ATRA) Positioned for Growth After - GuruFocus
Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results - MarketBeat
Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates - Investing.com
Atara Biotherapeutics 2Q 2026: Revenue $0.63M, Net loss $(9.0)M — 10-Q Summary - TradingView
Atara Biotherapeutics: Q2 Earnings Snapshot - AOL.com
BRIEF-Atara Biotherapeutics Q2 EPS USD -0.32 - TradingView
Atara Biotherapeutics Inc (ATRA) 財務データ
収益
当期純利益
現金流量
EPS
Atara Biotherapeutics Inc (ATRA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nguyen AnhCo | Director |
Aug 17 '26 |
Proposed Sale |
8.36 |
5,062 |
42,318 |
0 |
| Nguyen AnhCo | President and CEO |
Aug 17 '26 |
Sale |
8.08 |
5,062 |
40,883 |
132,775 |
| Nguyen AnhCo | President and CEO |
May 18 '26 |
Sale |
9.13 |
5,241 |
47,845 |
137,837 |
| Grant-Huerta Yanina | Chief Accounting Officer |
May 18 '26 |
Sale |
9.13 |
2,414 |
22,036 |
49,636 |
| Nguyen AnhCo | Director |
May 18 '26 |
Proposed Sale |
10.48 |
5,981 |
62,681 |
0 |
| Grant-Huerta Yanina | Officer |
May 18 '26 |
Proposed Sale |
10.48 |
2,754 |
28,862 |
0 |
| Panacea Innovation Ltd | 10% Owner |
May 07 '26 |
Sale |
10.10 |
313,446 |
3,165,021 |
1,011,000 |
| EcoR1 Capital, LLC | 10% Owner |
May 07 '26 |
Buy |
9.35 |
507,407 |
4,744,255 |
1,552,000 |
| Panacea Innovation Ltd | 10% Owner |
May 07 '26 |
Proposed Sale |
10.10 |
313,446 |
3,165,021 |
0 |
| Panacea Innovation Ltd | 10% Owner |
Mar 17 '26 |
Option Exercise |
0.00 |
259,163 |
26 |
307,899 |
0.68%
3.98%
大文字化:
|
ボリューム (24 時間):